Urolithin A in Elite Runners: Recovery Signal, No Performance Proof

Urolithin A has a credible case in people whose muscles have lost some mitochondrial function with age. In highly trained runners, the first dedicated randomized trial found something narrower: lower perceived effort and less evidence of muscle damage, but no statistically significant advantage in 3000 m performance, VO2max, or muscle respiratory capacity.

That result matters because urolithin A's best-known action is selective mitochondrial housekeeping. It promotes mitophagy, the process by which cells identify and remove damaged mitochondria, then replenish the network. A supplement built to clear broken machinery may have less to add when years of high-volume endurance training have already maintained much of it.

A ceiling test for mitochondrial repair

Urolithin A is a metabolite produced when gut microbes process ellagitannins, compounds found in foods such as pomegranate, walnuts, and berries. But people vary sharply in their ability to make it from food. Some are low producers or non-producers, which makes a pomegranate-heavy strategy a poor substitute for a standardized intervention. A 2023 review of urolithins and the gut microbiota describes this variability. The human trials discussed here used 1,000 mg per day of synthetic Mitopure, avoiding that conversion step.

Mechanistic reviews link urolithin A to PINK1/Parkin-dependent mitophagy, a pathway triggered by dysfunctional or depolarized mitochondria. Faitg and colleagues' 2024 review describes this muscle-aging rationale, and a 2026 comparative review likewise distinguishes urolithin A's damage-responsive mitophagy from spermidine's broader autophagy effects.

These reviews make the athlete question more interesting, not less. Signaling through a quality-control pathway does not guarantee a meaningful performance gain. The pathway needs impaired mitochondria to remove. Elite training does not make mitochondria immortal, unfortunately for anyone trying to dodge intervals, but it can leave less dysfunctional material for a mitophagy-focused intervention to clear.

What the athlete trial actually tested

Whitfield et al. (2025) conducted the first randomized, double-blind, placebo-controlled trial of urolithin A in trained athletes. The study enrolled 42 highly trained male distance runners, classified as tier 3–4 and running more than 70 km per week. Participants took 1,000 mg per day of urolithin A or placebo for four weeks during an altitude training camp at 1,700–2,200 meters.

The investigators split the work into two cohorts. Cohort A included 22 runners and assessed performance outcomes; only 11 runners per group received urolithin A or placebo. Cohort B included 20 runners and provided mechanistic measures from skeletal muscle.

The performance result was negative by the standard that matters for a supplement claim: urolithin A did not significantly outperform placebo in a 3,000 m time trial. The VO2max group-by-time interaction also missed statistical significance (p=0.138). The publication materials provided here do not report a confidence interval for that comparison, so the study cannot define the likely size of any true benefit with precision.

Within the urolithin A group, VO2max improved with a large standardized effect size (Cohen's d=0.83). That observation does not establish that the supplement caused the improvement, because the placebo-controlled between-group comparison was non-significant. It does, however, leave the trial inconclusive rather than proving that the true effect is zero. With 11 participants per group, the performance cohort had limited precision.

The runners taking urolithin A also reported a significant reduction in rating of perceived exertion (RPE), and the trial found lower creatine kinase and other indirect markers of muscle damage. Those outcomes may matter to athletes facing dense training blocks, but they are not the same endpoint as faster racing. A lower RPE can be useful; it cannot be converted into seconds saved without direct performance evidence.

Pathway activation did not become better respiration

Cohort B produced the study's most revealing contrast. Skeletal-muscle proteomics showed increased mitochondrial pathways and higher mitophagy markers, with a Cohen's d of 0.74. Yet high-resolution in situ respirometry in permeabilized muscle-fiber bundles found no improvement in mitochondrial respiratory capacity.

This is a real mechanistic limitation, not a technical footnote. Proteomic evidence shows that molecular pathways changed. It does not prove that the muscle gained respiratory capacity, and the respirometry result did not show such a gain after four weeks. The finding fits the hypothesis that trained runners had too little dysfunctional mitochondrial substrate for added mitophagy signaling to translate into substantial remodeling. It remains a hypothesis: the trial did not directly measure each runner's burden of damaged mitochondria or prove that substrate scarcity caused the null respiratory result.

Why older-adult findings do not automatically transfer

The athlete trial contrasts with randomized trials in populations more likely to have impaired baseline mitochondrial function. In a double-blind, placebo-controlled four-month trial, Liu et al. (2022) gave 1,000 mg per day of urolithin A to older adults with reduced muscle function. The study reported improved muscle endurance and 6-minute walk distance, alongside mitochondrial biomarker changes in skeletal muscle. It did not assess VO2max, so it cannot support a VO2max claim in older adults.

A separate four-month randomized trial in middle-aged adults by Singh et al. (2022) reported about a 10% improvement in VO2max, as well as improved muscle strength, exercise performance, and mitochondrial gene and protein expression. It also found lower C-reactive protein and plasma acylcarnitines. Those are encouraging findings, though CRP and acylcarnitines are biomarkers, not direct proof that anti-inflammatory effects caused better exercise outcomes.

A 2024 systematic review covering five human studies and about 250 healthy participants concluded that urolithin A had consistent effects on aging-related, mitochondrial, and muscle-function measures in older and middle-aged groups. It found no prior randomized trial in trained athletes. The new runner trial fills that gap, but it does not erase the population difference.

Duration may also help explain the discrepancy. The positive muscle and mitochondrial studies used four months of supplementation; Whitfield and colleagues used four weeks. No published evidence here establishes whether a longer course would improve respiratory capacity or race performance in trained athletes. It could reveal a delayed effect, or it could leave the same ceiling intact.

Recovery is plausible; ergogenic claims are premature

Urolithin A has biological effects beyond mitophagy. A randomized trial by Denk et al. (2025) reported effects on age-related immune decline and documented anti-inflammatory signaling that included NF-κB suppression. Together with the lower CRP and acylcarnitines in the middle-aged trial, this offers a plausible explanation for the lower RPE and muscle-damage markers in runners. Plausible is the right word: neither trial establishes that NF-κB suppression caused those athlete outcomes.

The altitude camp further complicates performance interpretation. Altitude exposure can itself drive erythropoietic and mitochondrial adaptations in both groups. A small trial would need to distinguish any supplement effect from those large concurrent training adaptations. The camp does not invalidate the study, but it makes a small urolithin A-specific VO2max effect harder to isolate.

Generalizability has other limits. The athlete trial enrolled only men, so it cannot answer whether female athletes respond similarly. The older and middle-aged comparison trials also enrolled men. In addition, the human efficacy evidence uses the Amazentis Mitopure formulation, and the available evidence has no independent replication using another urolithin A source or manufacturer. Industry involvement in the earlier positive trials deserves attention when weighing the full evidence base.

Verdict

For older or middle-aged men with reduced baseline muscle and mitochondrial function, four months of 1,000 mg daily urolithin A has randomized-trial support for improved functional and mitochondrial outcomes. For highly trained male distance runners, four weeks at the same dose did not demonstrate a performance advantage over placebo or improve mitochondrial respiratory capacity.

An athlete might reasonably view urolithin A as an unproven recovery adjunct, based on lower RPE and indirect muscle-damage markers in one small trial. They should not buy it expecting faster 3,000 m times or a verified VO2max boost. An adequately powered, longer placebo-controlled study outside an altitude camp is the experiment that could settle that question.